SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 12)*

Eledon Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☑ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons BIOTECHNOLOGY VALUE FUND L P
2	Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 6,061,390.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 6,061,390.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 6,061,390.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 7.0 %
12		Type of Reporting Person (See Instructions) PN

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons BVF I GP LLC
2		Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)
3		Sec Use Only
4		Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 6,061,390.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 6,061,390.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 6,061,390.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐

11	Percent of class represented by amount in row (9)	7.0 %
12	Type of Reporting Person (See Instructions)	OO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	BIOTECHNOLOGY VALUE FUND II LP
2	Check the appropriate box if a member of a Group (see instructions)	☑ (a) ☐ (b)
3	Sec Use Only	
4	Citizenship or Place of Organization	DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power	0.00
	6 Shared Voting Power	2,173,905.00
	7 Sole Dispositive Power	0.00
	8 Shared Dispositive Power	2,173,905.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	2,173,905.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	☐
11	Percent of class represented by amount in row (9)	2.6 %
12	Type of Reporting Person (See Instructions)	PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	BVF II GP LLC
2	Check the appropriate box if a member of a Group (see instructions)	

	☑ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 2,173,905.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 2,173,905.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 2,173,905.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 2.6 %	
12	Type of Reporting Person (See Instructions) OO	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Biotechnology Value Trading Fund OS LP	
2	Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization CAYMAN ISLANDS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 377,015.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power

		377,015.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	377,015.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	☐
11	Percent of class represented by amount in row (9)	0.4 %
12	Type of Reporting Person (See Instructions)	PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	BVF Partners OS Ltd.
2	Check the appropriate box if a member of a Group (see instructions)	☑ (a) ☐ (b)
3	Sec Use Only	
4	Citizenship or Place of Organization	CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power	0.00
	6 Shared Voting Power	377,015.00
	7 Sole Dispositive Power	0.00
	8 Shared Dispositive Power	377,015.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	377,015.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	☐
11	Percent of class represented by amount in row (9)	0.4 %
12	Type of Reporting Person (See Instructions)	CO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons BVF GP HOLDINGS LLC	
2	Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 8,235,295.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 8,235,295.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 8,235,295.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 9.5 %	
12	Type of Reporting Person (See Instructions) OO	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons BVF PARTNERS L P/IL	
2	Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each	5	Sole Voting Power 0.00
	6	Shared Voting Power

Reporting Person With:		8,655,393.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 8,655,393.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 8,655,393.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 9.99 %
12		Type of Reporting Person (See Instructions) IA, PN

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons BVF INC/IL
2		Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)
3		Sec Use Only
4		Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 8,655,393.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 8,655,393.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 8,655,393.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 9.99 %
12		Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons LAMPERT MARK N	
2	Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 8,655,393.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 8,655,393.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 8,655,393.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 9.99 %	
12	Type of Reporting Person (See Instructions) IN	

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Eledon Pharmaceuticals, Inc.

(b) Address of issuer's principal executive offices:

19800 MACARTHUR BLVD., SUITE 250, IRVINE, CA 92612

Item 2.

(a) Name of person filing:

Biotechnology Value Fund, L.P. ("BVF") BVF I GP LLC ("BVF GP") Biotechnology Value Fund II, L.P. ("BVF2") BVF II GP LLC ("BVF2 GP") Biotechnology Value Trading Fund OS LP ("Trading Fund OS") BVF Partners OS Ltd. ("Partners OS") BVF GP Holdings LLC ("BVF GPH") BVF Partners L.P. ("Partners") BVF Inc. Mark N. Lampert ("Mr. Lampert") Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

(b) Address or principal business office or, if none, residence:

Biotechnology Value Fund, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF I GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Fund II, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF II GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Trading Fund OS LP PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF Partners OS Ltd. PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF GP Holdings LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Partners L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Mark N. Lampert 44 Montgomery St., 40th Floor San Francisco, California 94104

(c) Citizenship:

Biotechnology Value Fund, L.P. Delaware BVF I GP LLC Delaware Biotechnology Value Fund II, L.P. Delaware BVF II GP LLC Delaware Biotechnology Value Trading Fund OS LP Cayman Islands BVF Partners OS Ltd. Cayman Islands BVF GP Holdings LLC Delaware BVF Partners L.P. Delaware BVF Inc. Delaware Mark N. Lampert United States

(d) Title of class of securities:

Common Stock, $0.001 par value

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on September 30, 2026, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held an aggregate of 4,419.93 shares of Series X Convertible Preferred Stock (the "Series X Preferred"), convertible for an aggregate of 245,552 Shares. Each share of the Series X Preferred is convertible into 55.5556 Shares. The Series X Preferred may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the number of Shares then issued and outstanding (the "Series X Blocker"). As of the close of business on September 30, 2026, the Series X Blocker prohibits the conversion of all of the Series X Preferred held by the Reporting Persons and the Partners Managed Account. As of the close of business on September 30, 2026, the Reporting Persons and the Partners Managed Account held an aggregate of 21,488.57 shares of Series X1 Convertible Preferred Stock (the "Series X1 Preferred"), convertible for an aggregate of 1,193,810 Shares. Each share of the Series X1 Preferred is convertible into 55.5556 Shares. The Series X1 Preferred may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the number of Shares then issued and outstanding (the "Series X1 Blocker"). As of the close of business on September 30, 2026, the Series X1 Blocker prohibits the conversion of all of the Series X1 Preferred held by the Reporting Persons and the Partners Managed Account. As of the close of business on September 30, 2026, the Reporting Persons and the Partners Managed Account held an aggregate of 15,247,782 Pre-Funded Warrants (the "Pre-Funded Warrants") exercisable into an aggregate of 15,247,782 Shares. Each Pre-Funded Warrant is exercisable immediately, has an exercise price

per Share of $0.001 and expires when exercised in full. Subject to limited exceptions, a holder of the Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after giving effect to such exercise (the "Pre-Funded Blocker"). As of the close of business on September 30, 2026, the Pre-Funded Blocker limits the exercise of the Pre-Funded Warrants held by the Reporting Persons and the Partners Managed Account to 2,362,111 out of 15,247,782 Shares underlying the Pre-Funded Warrants held by them. As of the close of business on September 30, 2026, the Reporting Persons and the Partners Managed Account held an aggregate of 5,844,153 Tranche A Warrants (the "Tranche A Warrants") exercisable into an aggregate of 5,844,153 Shares or Pre-Funded Warrants (the "Tranche A Pre-Funded Warrants") in lieu thereof. The Tranche A Warrants are exercisable at any time at a price of $3.00 per Share and expire on May 5, 2028. The Tranche A Warrants may be exercised for, at the holder's discretion, either (i) Shares or (ii) in the event that the Tranche A Blocker (as defined below) applies, a Tranche A Pre-Funded Warrant to purchase a number of Shares equal to the number of Shares as to which the Tranche A Warrant is being exercised. A holder of Tranche A Warrants will not have the right to exercise any portion of such warrants for Shares if the holder of such warrants, together with its Attribution Parties (as defined in the Form of Tranche A Warrant to Purchase Common Stock or Pre-Funded Warrants), would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after giving effect to such exercise (the "Tranche A Blocker"). As of the close of business on September 30, 2026, the Tranche A Blocker prohibits the exercise of all of the Tranche A Warrants held by the Reporting Persons and the Partners Managed Account into Shares. The Tranche A Pre-Funded Warrants are exercisable at any time at a price of $0.001 per Share and do not expire. A holder of Tranche A Pre-Funded Warrants will not have the right to exercise any portion of such warrants to the extent that after giving effect to such issuance after exercise, the holder of such warrants, together with its Attribution Parties (as defined in the Form of Pre-Funded Warrant to Purchase Common Stock), would beneficially own in excess of 9.99% of the outstanding Shares (the "Tranche A Pre-Funded Warrants Blocker"). As of September 30, 2026, to the extent the Reporting Persons and the Partners Managed Account exercised the Tranche A Warrants held by them for Tranche A Pre-Funded Warrants, the Tranche A Pre-Funded Warrants Blocker would prohibit the exercise of all such Tranche A Pre-Funded Warrants into Shares. As of the close of business on September 30, 2026 (i) BVF beneficially owned 6,061,390 Shares, including 2,362,111 Shares underlying certain Pre-Funded Warrants held by it and excluding (a) 5,308,151 Shares underlying certain Pre-Funded Warrants held by it, (b) 122,833 Shares underlying the Series X Preferred held by it, (c) 641,084 Shares underlying the Series X1 Preferred held by it, and (d) 3,084,090 Shares underlying the Tranche A Warrants held by it, (ii) BVF2 beneficially owned 2,173,905 Shares, excluding (a) 96,611 Shares underlying the Series X Preferred held by it, (b) 385,342 Shares underlying the Series X1 Preferred held by it, (c) 6,435,790 Shares underlying the Pre-Funded Warrants held by it, and (d) 2,446,209 Shares underlying the Tranche A Warrants held by it, and (iii) Trading Fund OS beneficially owned 377,015 Shares, excluding (a) 19,222 Shares underlying the Series X Preferred held by it, (b) 126,907 Shares underlying the Series X1 Preferred held by it, (c) 878,445 Shares underlying the Pre-Funded Warrants held by it, and (d) 252,291 Shares underlying the Tranche A Warrants held by it. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 6,061,390 Shares beneficially owned by BVF. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 2,173,905 Shares beneficially owned by BVF2. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 377,015 Shares beneficially owned by Trading Fund OS. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 8,235,295 Shares beneficially owned in the aggregate by BVF and BVF2. Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 8,655,393 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 43,083 Shares held in the Partners Managed Account, which excludes (a) 6,885 Shares underlying the Series X Preferred held by it, (b) 40,474 Shares underlying the Series X1 Preferred held by it, (c) 263,285 Shares underlying the Pre-Funded Warrants held by it, and (d) 61,563 Shares underlying the Tranche A Warrants held by it. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 8,655,393 Shares beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 8,655,393 Shares beneficially owned by BVF Inc. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based upon a denominator that is the sum of (i) 81,261,152 Shares outstanding as of August 10, 2026, which is the total number of Shares outstanding as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026, (ii) 3,017,311 Shares issued to the Reporting Persons on September 30, 2026 upon the conversion of certain Series X1 Preferred previously held by them, and (iii) 2,362,111 Shares issuable upon the exercise of certain Pre-Funded Warrants held by the Reporting Persons, as applicable. As of the close of business on September 30, 2026 (i) BVF beneficially owned approximately 7.0% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.6% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 7.0% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own

approximately 2.6% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.5% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding Shares (less than 1% of the outstanding Shares is held in the Partners Managed Account). %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote:

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit 99.1 to Amendment No. 1 to the Schedule 13G filed with the Securities and Exchange Commission on October 5, 2020.

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BIOTECHNOLOGY VALUE FUND L P

Signature: /s/ Mark N. Lampert

Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF I GP LLC

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BIOTECHNOLOGY VALUE FUND II LP

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF II GP LLC

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

Biotechnology Value Trading Fund OS LP

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF Partners OS Ltd.

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF GP HOLDINGS LLC

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF PARTNERS L P/IL

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF INC/IL

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

LAMPERT MARK N

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert
Date: 11/16/2026